Nagaraj S, Ziske C, Strehl J, Messmer D, Sauerbruch T, Schmidt-Wolf I G H
Department of Internal Medicine I, Rheinische Friedrich-Wilhelms-Universität, Sigmund Freud Strasse 25, 53105 Bonn, Germany.
Int Immunol. 2006 Aug;18(8):1279-83. doi: 10.1093/intimm/dxl059. Epub 2006 Jun 13.
Ductal pancreatic adenocarcinoma is the fourth leading cause of cancer death in the Western world. Unfortunately, recent advances in diagnostics, staging and therapy have not resulted in significant improvements. Thus, new approaches are necessary to improve the outcome of patients with exocrine pancreatic cancer. We tested triggering of specific T lymphocytes in vivo by using the immunocompetent mouse strain C57BL/6. In the present study, we tried to enhance the anti-tumor effect against pancreatic carcinoma by supplementary triggering of NKT cells in vivo. We challenged Panc02 tumor-bearing mice by intratumoral vaccination with alpha-galactosylceramide (alpha-GalCer)-loaded dendritic cells (DCs). A significant expansion of IFNgamma-producing NKT cells was observed which also correlated with decrease in tumor growth in vivo. Hence, DCs loaded with alpha-GalCer could lead to a novel treatment option for patients with pancreatic cancer.
胰腺导管腺癌是西方世界癌症死亡的第四大主要原因。不幸的是，近期在诊断、分期和治疗方面的进展并未带来显著改善。因此，需要新的方法来改善外分泌性胰腺癌患者的治疗结果。我们使用具有免疫活性的小鼠品系C57BL/6在体内测试了特异性T淋巴细胞的触发。在本研究中，我们试图通过在体内补充触发NKT细胞来增强对胰腺癌的抗肿瘤作用。我们通过用负载α-半乳糖神经酰胺（α-GalCer）的树突状细胞（DCs）进行瘤内接种来攻击携带Panc02肿瘤的小鼠。观察到产生IFNγ的NKT细胞显著扩增，这也与体内肿瘤生长的减少相关。因此，负载α-GalCer的DCs可能为胰腺癌患者带来一种新的治疗选择。
